Improving Outcomes in HER2-Positive Breast Cancer: Analysis and Application of Evolving Data and Best Practices
Presented by Jame Abraham, MD, and Kelley D. Mayden, MSN, FNP, AOCNP®
From (1)Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio; (2)Legacy Wellmont Cancer Institute, Ballad Health, Bristol, Virginia
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2020;11(3):271–274 |
© 2020 Harborside™
Through expert, case-based discussion, Jame Abraham, MD, and Kelley Mayden, MSN, FNP, AOCNP®, presented existing and emerging data for current and investigational therapies for HER2-positive breast cancer and their associated adverse events, in addition to best practices for managing central nervous system metastases.
For access to the full length article, please sign in